

Title (en)
PHARMACEUTICAL COMPOSITION FOR TOPICAL USE THAT IS IN THE FORM OF A DISPERSED PHASE BASED ON AT LEAST ONE SHORT DIOL IN A CONTINUOUS FATTY PHASE AND COMPRISING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE

Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR TOPISCHEN ANWENDUNG IN FORM EINER DISPERGIERTEN PHASE BASIEREND AUF MINDESTENS EINEM KURZEN DIOL IN EINER KONTINUIERLICHEN FETTPHASE UND MIT MINDESTENS EINER ENTZÜNDUNGSCHEMMENDEN SUBSTANZ

Title (fr)
COMPOSITION PHARMACEUTIQUE A USAGE TOPIQUE SE PRESENTANT SOUS LA FORME D'UNE PHASE DISPERSEE A BASE D'AU MOINS UN DIOL COURT DANS UNE PHASE GRASSE CONTINUE ET COMPRENANT AU MOINS UNE SUBSTANCE ANTI-INFLAMMATOIRE

Publication
EP 4025182 A1 20220713 (FR)

Application
EP 20757647 A 20200804

Priority
• FR 1909117 A 20190809
• FR 2020051430 W 20200804

Abstract (en)
[origin: WO2021028632A1] Pharmaceutical composition for topical use (E1) comprising a gelled phase (A1) dispersed in a continuous phase (A2), said pharmaceutical composition (E1) comprising: a gelled phase (A1) comprising at least one anti-inflammatory substance (A1) and at least one diol having from three to eight carbon atoms and represented either by formula (Ia): Ra 1-(Rb 1)(OH)-(OH)(Rc 1)(Rd1) (Ia), wherein each of the Ra1, Rb1, Rc1 and Rd1 radicals represent, independently of one another, a hydrogen atom or saturated aliphatic radical having from one to five carbon atoms, or by formula (Ib): Ra 1-C(Rb 1)(OH)-[C(Rc 1)(Rf1)]t-C(OH)(Rc 1)(Rd 1) (Ib), wherein t is equal to one, two or three, each of the Ra 1, Rb 1, Rc 1 Rd 1, Re 1 and Rf 1 radicals represent, independently of one another, a hydrogen atom or saturated aliphatic radical having from one to five carbon atoms, it being understood that at least one of the Ra 1 or Rb 1 radicals and/or at least one of the Rc 1 or Rd 1 radicals do not represent a hydrogen atom, a fatty phase (A2) comprising at least one oil and an emulsifying system (S) comprising a combination of at least one emulsifying surfactant (S1) and at least one emulsifying surfactant (S2).

IPC 8 full level
A61K 9/00 (2006.01); **A61K 9/107** (2006.01); **A61K 31/00** (2006.01); **A61K 47/10** (2017.01); **A61K 47/26** (2006.01); **A61K 47/32** (2006.01); **A61L 15/00** (2006.01); **A61P 17/00** (2006.01)

CPC (source: CN EP US)
A61K 9/0014 (2013.01 - CN EP US); **A61K 9/107** (2013.01 - CN EP US); **A61K 9/7015** (2013.01 - CN); **A61K 9/7023** (2013.01 - CN); **A61K 31/192** (2013.01 - CN EP US); **A61K 31/196** (2013.01 - CN EP US); **A61K 31/216** (2013.01 - US); **A61K 31/381** (2013.01 - CN EP US); **A61K 31/404** (2013.01 - US); **A61K 31/405** (2013.01 - CN EP); **A61K 47/10** (2013.01 - CN EP US); **A61K 47/26** (2013.01 - CN EP); **A61K 47/32** (2013.01 - CN EP); **A61K 47/34** (2013.01 - US); **A61P 3/10** (2017.12 - CN); **A61P 17/00** (2017.12 - CN EP); **A61P 17/16** (2017.12 - CN); **A61P 25/06** (2017.12 - CN); **A61P 29/00** (2017.12 - CN); **A61P 31/04** (2017.12 - CN); **A61K 9/7015** (2013.01 - EP); **Y02A 50/30** (2017.12 - EP)

Citation (search report)
See references of WO 2021028632A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
FR 3099697 A1 20210212; **FR 3099697 B1 20220708**; CN 114502152 A 20220513; EP 4025182 A1 20220713; JP 2022542680 A 20221006; US 2022288022 A1 20220915; WO 2021028632 A1 20210218

DOCDB simple family (application)
FR 1909117 A 20190809; CN 202080053485 A 20200804; EP 20757647 A 20200804; FR 2020051430 W 20200804; JP 2022505576 A 20200804; US 202017632664 A 20200804